Hydropothecary (CVE:THCX)‘s stock had its “buy” rating restated by stock analysts at Eight Capital in a research note issued to investors on Thursday. They currently have a C$3.50 price target on the stock. Eight Capital’s price objective points to a potential upside of 44.03% from the stock’s previous close.

Shares of Hydropothecary (CVE:THCX) traded down C$0.15 during trading on Thursday, hitting C$2.43. The company’s stock had a trading volume of 1,362,113 shares, compared to its average volume of 521,248. Hydropothecary has a fifty-two week low of C$0.68 and a fifty-two week high of C$3.00.

TRADEMARK VIOLATION WARNING: “Hydropothecary (THCX) Stock Rating Reaffirmed by Eight Capital” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/30/hydropothecary-thcx-given-a-c3-50-price-target-by-eight-capital-analysts.html.

Hydropothecary Company Profile

The Hydropothecary Corporation produces and distributes medical marijuana. The company is based in Gatineau, Canada.

Receive News & Ratings for Hydropothecary Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hydropothecary Corp and related companies with MarketBeat.com's FREE daily email newsletter.